301 Binney Street
3rd Floor
Cambridge, MA 02142
United States
857 259 3860
https://scholarrock.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 150
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Jay Thomas Backstrom M.D., M.P.H. | President, CEO & Director | 686,49k | N/A | 1955 |
Mr. Edward H. Myles MBA | CFO, COO & Treasurer | 668,49k | N/A | 1972 |
Ms. Junlin Ho J.D. | General Counsel & Corporate Secretary | 563,73k | N/A | 1979 |
Mr. Mo Qatanani Ph.D. | Chief Scientific Officer | N/A | N/A | 1974 |
Rushmie Nofsinger | Vice President of Corporate Affairs & Investor Relations | N/A | N/A | N/A |
Ms. Caryn Parlavecchio | Chief Human Resources Officer | N/A | N/A | 1972 |
Ms. Lisa Amaya Price | Senior Vice President of Human Resources | N/A | N/A | N/A |
Ms. Erin Moore | Senior Vice President of Finance | N/A | N/A | 1975 |
Mr. Ryan Iarrobino | Senior Vice President of Clinical Development & Operations | N/A | N/A | N/A |
Dr. Jing L. Marantz M.B.A., M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1965 |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
El ISS Governance QualityScore de Scholar Rock Holding Corporation, a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 3; Tablero: 7; Derechos de los accionistas: 8; Compensación: 9.